Digestive Diseases and Sciences

, Volume 45, Issue 6, pp 1045–1052

Review: Gene Therapy for Cancer:

  • Gregory Kouraklis


Gene therapy is a new form of therapeutic intervention with applications in many areas of medical treatment. There are still many technical difficulties to be overcome, but recent advances in the molecular and cellular biology of gene transfer have made it likely that gene therapy will soon start to play an increasing role in clinical practice and particularly in the treatment of cancer. The first clinical gene transfer in an approved protocol took place exactly 10 years ago, and it was for the transfer of gene-marked immune cells into patients with advanced cancer. Now there are 218 active clinical protocols in the United States, and they have involved over 2000 patients worldwide. Among the conditions and diseases for which gene transfer is being tried as treatment, cancer comes first with 130 clinical trials. Fundamental research in the mechanisms of cancer and the development of molecular biology tools are crucial for the success of the treatments in the future. The identification of tumor rejection antigens from a variety of cancers and the immune response that is defective in cancer patients are important topics for future studies. The evaluation of gene therapy combinations involving use of tumor suppressor genes and constructs that inactivate oncogenes is also another important area for future research. The future improvement of present viruses as well as the use of new viral vectors will likely expand the applicability and efficacy of gene therapy. During the next decade technological developments, particularly in the areas of gene delivery and cell transplantation, will be critical for the successful clinical practice of gene therapy.

gene therapy cancer vector 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rosenberg SA: The development of new cancer therapies based on the molecular identification of cancer regression antigens. Sci Am 1:90-100, 1995Google Scholar
  2. 2.
    Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells iin vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994PubMedGoogle Scholar
  3. 3.
    Habib NA, Ding S, Ei-Masry R, Dalla Serra G, Mikhail NE, Izzi G: Contrasting effects of direct p53 DNA injection in primary and secondary liver tumors. Tumor Target 1:295-298, 1995Google Scholar
  4. 4.
    Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, Carson C: Interleukin-2 gene therapy in a patient with glioblastoma: Using a retrovirus vector. Gene Ther 2:164-167, 1995PubMedGoogle Scholar
  5. 5.
    Raftopoulos J, Kouraklis G: Dysfunction of the E-cadherin/ catenin cell adhesion cascade in epithelial cancers. Oncol Rep 3:793-803, 1996Google Scholar
  6. 6.
    Mastrangelo MJ, Schultz S, Kane M: Newer immunologic approaches to the treatment of patient with cancer. Semin Oncol 15:589-594, 1988PubMedGoogle Scholar
  7. 7.
    Smith KA: Interleukin 2: Inception, impact and implications. Science 240:1169-1170, 1988PubMedGoogle Scholar
  8. 8.
    Trial: Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2.Hum Gene Ther 3:75-90, 1992PubMedGoogle Scholar
  9. 9.
    Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: in vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 256:1550-1552, 1992PubMedGoogle Scholar
  10. 10.
    Zhang Y: Retroviral vector-mediated transduction of K-ras antisense RNA into human cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 4:451-460, 1993PubMedGoogle Scholar
  11. 11.
    Friedmann T: Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 70(suppl):1810-1817, 1992PubMedGoogle Scholar
  12. 12.
    Samara G, Sawicki MP, Hurwitz M, Passaro E: Molecular biology and therapy of disease. Am J Surg 165:720-727, 1993PubMedGoogle Scholar
  13. 13.
    Kouraklis G: Progress in cancer gene therapy. Acta Oncol 38:675-683, 1999PubMedGoogle Scholar
  14. 14.
    Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strans M: Adenovirally transferred p16 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 3:316-319, 1997Google Scholar
  15. 15.
    Crystal RG: Transfer of gene to humans: Early lessons and obstacles to success. Science 270:404-410 1995PubMedGoogle Scholar
  16. 16.
    Coffin JM: Retroviradae and their replication. In Virology, 2nd ed. BN Fields, DM Knipe (eds). New York, Raven Press, 1990.Google Scholar
  17. 17.
    Watson JD, Hopkins NH, Roberts JW, Steitz JA, Weiner AM: Molecular Biology of the Gene, 4th ed. New York, Benjamin-Cummings, 1988Google Scholar
  18. 18.
    Miller AD: Retrovirus packaging cells. Hum Gene Ther 1:5-14, 1990.PubMedGoogle Scholar
  19. 19.
    Herrmann F: Cancer gene therapy: Principles, problems, and perspectives. J Mol Med 73:157-163, 1995PubMedGoogle Scholar
  20. 20.
    Gelinas C, Temin HM: Nondefective spleen necrosis virusderived vectors define the upper size limit for packaging reticuloendotheliosis viruses. Proc Natl Acad Sci USA 83:9211-9215, 1986PubMedGoogle Scholar
  21. 21.
    Letvin NL: Progress in the development of an HIV-1 vaccine. Science 280:1875-1879, 1998PubMedGoogle Scholar
  22. 22.
    Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L: A third generation lentivirus vector with a contitional packaging system. J Virol 72:8463-8471, 1998PubMedGoogle Scholar
  23. 23.
    Horwitz MS: Adenoviridae and their replication. In Virology, 2nd ed. BN Fields, DM Knipe (eds). New York, Raven Press, 1990, pp 1679-1721Google Scholar
  24. 24.
    Trapnell BC, Gorziglia M: Gene therapy using adenoviral vectors. Curr Opin Biotechnol 5:617-625, 1994PubMedGoogle Scholar
  25. 25.
    Engelhardt JF, Ye X, Doranz B, Wilson JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91:6196-6200, 1994.PubMedGoogle Scholar
  26. 26.
    Engelhardt JF, Litzky L, Wilson JM: Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2A. Hum Gene Ther 5:1217-1229, 1994PubMedGoogle Scholar
  27. 27.
    Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM: Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11-22, 1996PubMedGoogle Scholar
  28. 28.
    Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT: A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and b-galactosidase. Proc Natl Acad Sci USA 93:5731-5736, 1996PubMedGoogle Scholar
  29. 29.
    Bridge E, Medghalchi S, Ubol S, Leesong M, Ketner G: Adenovirus early region 4 and viral DNA synthesis. Virology 193:794-801, 1993PubMedGoogle Scholar
  30. 30.
    Wang Q, Jia XC, Finer MH: A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther 2:775-783, 1995PubMedGoogle Scholar
  31. 31.
    Wang Q, Finer MH: Second generation adenovirus vectors. Nat Med 2:714-716, 1996PubMedGoogle Scholar
  32. 32.
    Gao GP, Yang Y, Wilson JM: Biology of adenoviral vectors deleted of E1 and E4 for liver-directed gene therapy. J Virol 70:8934-8943, 1996PubMedGoogle Scholar
  33. 33.
    Latchman DS: Herpes simplex virus vectors for gene therapy. Mol Biotechnol 2:179-195, 1994PubMedGoogle Scholar
  34. 34.
    Neve RL, Geller AJ: A defective herpes simplex virus vector system for gene delivery into the brain: Comparison with alternative gene delivery systems and usefulness for gene therapy. Clin Neurosci 3:262-267, 1996Google Scholar
  35. 35.
    Turner SL, Jenkins FJ: The roles of herpes simplex virus in neuroscience. J Neurovirol 3:110-125, 1997PubMedGoogle Scholar
  36. 36.
    Latchman DS: Herpes simplex virus vector for gene therapy. Mol Biotechnol 2:179-195, 1994PubMedGoogle Scholar
  37. 37.
    Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA: Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta. Ann Surg Oncol 2:151-159, 1995PubMedGoogle Scholar
  38. 38.
    Hodge JW, Abrams S, Schlom J, Kantor JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552-5555, 1994PubMedGoogle Scholar
  39. 39.
    Zhu N, Liggitt D, Liu Y, Debs R: Systematic gene expression after intravenous DNA delivery into adult mice. Science 261:209-211, 1993PubMedGoogle Scholar
  40. 40.
    Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SL: Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 90:11548-11552, 1993PubMedGoogle Scholar
  41. 41.
    Bunnell BA, Askari FK, Wilson JM: Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet 18:559-569, 1992PubMedGoogle Scholar
  42. 42.
    Cotten M, Wagner E, Zatloukal K, Philips S, Curiel DT, Birnstiel ML: High-efficiency receptor-mediated delivery of small and large (48 kb) gene constructs using the endosomedisruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci USA 89:6094-6098, 1992PubMedGoogle Scholar
  43. 43.
    Trial: Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther 3:339-410, 1992Google Scholar
  44. 44.
    Toneguzzo F, Keating A: Stable expression of selectable genes introduced into human hematopoietic stem cells by electric field mediated DNA transfer. Proc Natl Acad Sci USA 83:3496-3499, 1986PubMedGoogle Scholar
  45. 45.
    Sekhar M, Kotani H, Doren S, Agarwal R, McGarrity GJ, Dunbar CE: Retroviral transduction of CD34-enriched hematopoietic progenitor cells under serum-free conditions. Hum Gene Ther 7:33-38, 1996PubMedGoogle Scholar
  46. 46.
    Vile RG, Hart IR: Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 53:3860-3864, 1993PubMedGoogle Scholar
  47. 47.
    Cheng L, Ziegelhoffer PR, Yang NS: in vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 90:4455-4459, 1993PubMedGoogle Scholar
  48. 48.
    Nicolet CM, Burkholder JK, Gan J, Culp J, Kashmiri SV, Schlom J: Expression of a tumor-reactive antibody-interleukin-2 fusion protein after in vivo particle-mediated gene delivery. Cancer Ther 2:161-170, 1995Google Scholar
  49. 49.
    Sobol R, Scanlon KJ: Clinical protocols list. Cancer Gene Ther 2:225-234, 1995Google Scholar
  50. 50.
    Friedmann T: Progress toward human gene therapy. Science 244:1275-1281, 1989PubMedGoogle Scholar
  51. 51.
    Miller AD: Human gene therapy comes of age. Nature 357:455-460, 1992PubMedGoogle Scholar
  52. 52.
    Anderson WF: Human gene therapy. Science 256:808-813,1992PubMedGoogle Scholar
  53. 53.
    Friedmann T: A brief history of gene therapy. Nature Genet 2:93-98, 1992PubMedGoogle Scholar
  54. 54.
    Gutierrez AA, Lemoine NR, Sikora K: Gene therapy for cancer. Lancet 339:715-720, 1992PubMedGoogle Scholar
  55. 55.
    Anderson WF: Gene therapy for cancer. Hum Gene Ther 5:1-2, 1994PubMedGoogle Scholar
  56. 56.
    Eglitis M, Kantoft P, Gilboa E, Anderson WF: Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 230:1395-1398, 1985PubMedGoogle Scholar
  57. 57.
    Trial: The N2-TIL human gene transfer clinical protocol. Hum Gene Ther 1:73-92, 1990PubMedGoogle Scholar
  58. 58.
    Trial: The ADA human gene therapy clinical protocol. Hum Gene Ther 1:327-362, 1990PubMedGoogle Scholar
  59. 59.
    Anonymous: Cancer gene therapy annuall conference 1997: Trends and news. Hum Gene Ther 9:283-286, 1998 (editorial)Google Scholar
  60. 60.
    Anonymous: Clinical protocols. Cancer Gene Ther 2:67-74, 1995 (editorial)Google Scholar
  61. 61.
    ORDA Reports: Recombinant DNA Advisory Committee (RAC) data management report-December 1994.Hum Gene Ther 6:535-548, 1995Google Scholar
  62. 62.
    Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of the human MDR1.Science 257:99-103, 1995Google Scholar
  63. 63.
    Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L: Retrovirus mediate expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea induced toxicity in vitro and in vivo. Cancer Res 55:2608-26014, 1995PubMedGoogle Scholar
  64. 64.
    Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP: A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87:2579-2587, 1996PubMedGoogle Scholar
  65. 65.
    Jin X, Nguyen D, Zhang WW, Kyritsis AP, Roth JA: Cell cycle arrest and inhibition of tumor cell proliferation by the p16/ INK4 gene mediated by an adenovirus vector. Cancer Res 55:3250-3253, 1995PubMedGoogle Scholar
  66. 66.
    Xu HJ, Zhou Y, Seigne J, Perng GS, Mixon M, Zhang C: Enhanced tumor suppressor gene therapy via replicationdeficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 56:2245-2249, 1996PubMedGoogle Scholar
  67. 67.
    Dranoff G: Cancer gene therapy: Connecting basic research with clinical inquiry. J Clin Oncol 16:2548-2556, 1998PubMedGoogle Scholar
  68. 68.
    Bunnell BA, Askari FK, Wilson JM: Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet 18:559-569, 1992PubMedGoogle Scholar
  69. 69.
    Curiel DT, Wagner E, Cotten M, Birnstiel ML, Agarwal S, Li C: High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther 3:147-154, 1992PubMedGoogle Scholar
  70. 70.
    Kasahara N, Dozy AM, Kan YW; Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266:1373-1376, 1994PubMedGoogle Scholar
  71. 71.
    Roth JA: Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wild-type (normal) p53.Hum Gene Ther 7:861-874, 1996PubMedGoogle Scholar
  72. 72.
    Ghazal P, Lubon H, Fleckenstein B, Hennighausen L: Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. Proc Natl Acad Sci USA 84:3658-3662, 1987PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 2000

Authors and Affiliations

  • Gregory Kouraklis
    • 1
  1. 1.2nd Propedeutic Department of SurgeryAthens University, School of Medical SciencesAthensGreece

Personalised recommendations